INTRODUCTION {#s1}
============

Clonal evolution of mantle cell lymphoma (MCL) is still poorly understood. Intratumoral heterogeneity, subclonal architecture, and clonal dynamic changes after chemotherapy have been demonstrated ([@MCS004259TASC1]). The presence of Hodgkin/Reed--Sternberg (HRS)-like cells has been reported in rare patients suggesting clonal evolution HRS-like cells from MCL ([@MCS004259TASC11]; [@MCS004259TASC9]; [@MCS004259TASC7]). Interestingly, all these cases had scattered HRS-like cells in a background of typical MCL ([@MCS004259TASC2]; [@MCS004259TASC13]; [@MCS004259TASC5]; [@MCS004259TASC11]; [@MCS004259TASC4]; [@MCS004259TASC9]; [@MCS004259TASC7]). The mixed inflammatory microenvironment seen in classic Hodgkin lymphoma (CHL) was seldom observed, mimicking the so-called type I morphology with HRS-like cells in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) ([@MCS004259TASC3]; [@MCS004259TASC8]; [@MCS004259TASC14]). Current recommendations are against diagnosing or managing these cases as bona fide CHL ([@MCS004259TASC14]; [@MCS004259TASC12]). Therefore, it is still unclear if MCL can clonally evolve to CHL. Here, we report an exceedingly rare event in a patient with MCL, who developed a clonally related CHL after eradication of MCL and then relapsed again as blastoid MCL with additional genetic aberrations. Comprehensive genetic evidence indicates a divergent clonal evolution from a common precursor to MCL and CHL.

CASE PRESENTATION {#s2}
=================

A 70-yr-old male with a stage IV MCL ([Fig. 1](#MCS004259TASF1){ref-type="fig"}A--F) received four cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and lenalidomide, followed by two cycles of rituximab and high dose cytarabine (R-HiDAC), and 6 mo of lenalidomide maintenance. A year after the initial diagnosis, restaging PET showed new FDG avid hilar, abdominal, left inguinal nodes, and a new FDG avid focus in the right rib. Biopsy of the left inguinal lymph node and bilateral thoracic hilar nodes showed typical CHL and no evidence of MCL by both immunohistochemical and flow cytometric studies ([Fig. 1](#MCS004259TASF1){ref-type="fig"}G--M; [Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)). He was diagnosed with stage IV CHL, nodular sclerosing subtype, and treated with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD). Treatment was poorly tolerated and was complicated by anemia and thrombocytopenia requiring transfusions; therefore, only four cycles were administered. PET imaging at the end of the fourth cycle showed the persistence of disease in the left acetabulum, which was biopsied and showed blastoid MCL without pathologic evidence of CHL ([Fig. 1](#MCS004259TASF1){ref-type="fig"}N--S). The patient received radiation therapy to the localized disease. However, the patient relapsed postradiation in multiple bony sites. Currently, the patient is being treated with rituximab and ibrutinib and awaiting assessment of response.

![Pathologic features of MCL and CHL. (*A*) PET imaging showed diffuse involvement in lymph nodes, spleen, and bone marrow. (*B*) H&E morphology of MCL in bone marrow (×200). (*C*--*E*) Immunohistochemical stains of MCL including Cyclin D1 (*C*), Ki-67 (*D*), and TP53 (*E*). (*F*) Immunophenotype of MCL by flow cytometry (gated CD19^+^ B cells are shown). (Blue) κ restriction B cells, (red) λ restriction B cells. (*G*) PET imaging showed localized uptake in left inguinal node and ribs (red circle represents biopsied left inguinal node). (*H*) H&E morphology of CHL in the node (note the mixed inflammatory background including eosinophils and plasma cells; also see [Supplemental Fig. S1A](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)). (*I*--*L*) Immunohistochemical stains of CHL including Cyclin D1 (*I*, weak expression in HRS cells), CD30 (*J*), PDL1 (*K*), and PDL2 (*L*). (*M*) Immunophenotype of HRS cells by flow cytometry (FSC^hi^SSC^hi^CD30^+^CD40^+^CD95^+^ cells are gated). (*N*) PET imaging showed relapsed blastoid MCL (red circle represents the biopsied acetabulum lesion). (*O*) H&E morphology of blastoid MCL (×200). (*P*--*R*) Immunohistochemical stains of blastoid MCL including Cyclin D1 (*P*), Ki-67 (*Q*), and TP53 (*R*). (*S*) Immunophenotype of blastoid MCL by flow cytometry (CD19^+^ B cells are gated). (Blue) κ restricted population, (red) λ restricted population.](MCS004259Tas_F1){#MCS004259TASF1}

RESULTS {#s4}
=======

The findings of immunohistochemical studies on the three lymphomas are summarized in [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1). Cyclin D1 was expressed in MCL, CHL (HRS cells), and blastoid MCL ([Fig. 1](#MCS004259TASF1){ref-type="fig"}C,I,P). Ki-67 proliferation index and TP53 expression were low in MCL ([Fig. 1](#MCS004259TASF1){ref-type="fig"}D,E), whereas both were high in the blastoid MCL ([Fig. 1](#MCS004259TASF1){ref-type="fig"}O,R). HRS cells in CHL showed characteristic phenotype with the absence of CD20 ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)), strong expression of MUM-1 ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)) and strong CD30 ([Fig. 1](#MCS004259TASF1){ref-type="fig"}J), and up-regulation of PDL1 and PDL2 ([Fig. 1](#MCS004259TASF1){ref-type="fig"}K,L).

Chromosome analysis of the bone marrow aspirate involved by MCL revealed a complex karyotype with subclones in 12 of 20 metaphase cells. The chromosome abnormalities included *t*(11;14), the hallmark of MCL, and multiple numerical and structural chromosome abnormalities, including deletions of the short arms of Chromosomes 1, 8, 9, 12, and 17, and in the long arm of Chromosome 6, loss of Chromosomes Y, 9, and 13 and 21, three to four marker chromosomes, and a ring chromosome (not shown).

FISH analysis confirmed the IGH/*CCND1* fusion with a typical signal pattern in the bone marrow aspirate specimen with MCL ([Supplemental Fig. S2A](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)). FISH analysis using the *CCND1* break-apart probes confirmed the *CCND1* rearrangements in the HRS cells of the groin lymph node biopsy with CHL and in the acetabulum bone biopsy tissue with blastoid MCL ([Supplemental Fig. S2B,C](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)), with a complex signal pattern in both the HRS cells and in blastoid MCL cells. Thus, all three specimens with MCL, CHL, and blastoid MCL carried the *t*(11;14), with additional abnormalities in CHL and blastoid MCL.

FISH analysis using *PDL1/PDL2* probes, along with a centromere probe for Chromosome 9 as an internal control for copy-number assessment, showed a high level gain of *PDL1* and *PDL2* in 25%, and polysomy 9 in 60% of the HRS cells analyzed in groin tissue with CHL ([Supplemental Fig. S2D](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)). FISH analysis of the acetabulum tissue with blastoid MCL showed no evidence of *PDL1/2* amplification or translocations. However, loss of *PDL1/2* and one CEP9 copy was observed in 86% cells, consistent with loss of one Chromosome 9, which was also detected in the bone marrow specimen with MCL ([Supplemental Fig. S2D,E](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)).

A clonal *IGHV* gene rearrangement was identified in the original MCL ([Fig. 2](#MCS004259TASF2){ref-type="fig"}A) and was further characterized by NGS, which revealed a unique clonal sequence (IGHV3-23 IGHJ4) with a mutation rate of 3.5%, consistent with a mutated somatic hypermutation status. Comparative analysis of the CHL and blastoid MCL revealed an identical *IGHV* clonal sequence, also with a mutation rate of 3.5%, confirming clonal relatedness ([Fig. 2](#MCS004259TASF2){ref-type="fig"}B,C). NGS study using a targeted panel containing 400 genes identified somatic mutations in *TP53* p.R248Q*, NSD2* p.E1099K, and *IDH1* p.E262K in all three lymphomas ([Table 1](#MCS004259TASTB1){ref-type="table"}; [Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)). A subclonal *KMT2D* p.L3542Vfs\*13 (c.10624_10625delCT) mutation was detected in the initial MCL and was subsequently found in the CHL at a comparable allele fraction to the shared *TP53* variant, suggesting that this became the predominant clone; however, this *KMT2D* variant was not detected in the blastoid MCL. Instead, the blastoid MCL had additional *SETBP1* p.S568I and a different *KMT2D* variant p.F3966_Q3971 delins\* mutation that was not present in the initial MCL or CHL. In addition, *SEC22B-NOTCH2* gene fusion was detected in blastoid MCL but not reported in MCL or CHL.

![Molecular profiles of MCL and CHL. (*A*) Fragment analysis by PCR studies showed a clonal peak in IGH rearrangements (identical peaks are shared by all three lymphomas). Shown here is the initial MCL. (*B*) Next-generation sequencing studies (LymphoTrack assay) showed identical clones between MCL (*left*) and CHL (*right*). The same clone was also identified in blastoid MCL (not shown). (*C*) Alignment of identical IGHV sequences between all three lymphomas. (*D*,*E*) Copy-number plots for MCL (*D*) and blastoid MCL (*E*) showing shared broad copy-number gains on Chromosome arms 3q and broad copy-number losses on 8p, 9, and 13. In the original MCL, broad copy-number loss of 6q is noted; however, relapsed MCL showed gains on 6p, 7, 11q, and 15q25--26, which were not appreciated in the original MCL. (*F*) Graphic illustration of divergent clonal evolution of a common precursor to CHL and MCL. Genetic aberrations are shown accordingly. (*G*) Immunophenotype of the three lymphomas.](MCS004259Tas_F2){#MCS004259TASF2}

###### 

Somatic variants detected in the patient

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene             Chromosome     HGVS DNA reference                          HGVS protein reference      Variant type      Predicted effect   dbSNP ID      Genotype
  ---------------- -------------- ------------------------------------------- --------------------------- ----------------- ------------------ ------------- --------------
  *TP53*           17p13.1\       NM_000546.5: c.743G\>A                      p.Arg248Gln                 SNV; missense     Substitution       rs11540652    Heterozygous
                   17:7577538                                                                                                                                

  *IDH1*           2q34\          NM_005896: c.784G\>A                        p.Glu262Lys                                                      NA            
                   2:209106784                                                                                                                               

  *NSD2 (WHSC1)*   4p16.3\        NM_001042424; c.3295G\>A                    p.Glu1099Lys                SNV; missense     Substitution       rs772470710   Heterozygous
                   4:1962801                                                                                                                                 

  *KMT2D (MLL2)*   12q13.12\      NM_003482; c.10624_10625delCT               p.Leu3542Valfs\*13          Indel; nonsense   Frameshift         NA            Heterozygous
                   12: 49427964                                                                                                                              

  *KMT2D (MLL2)*   12q13.12\      NM_00348; c.11897_11911delTTCAACAGCAGCAGC   p.Phe3966_Gln3971delins\*   Indel; nonsense   Nonsense           NA            Heterozygous
                   12:49426576                                                                                                                               

  *SETBP1*         18q12.3\       NM_015559; c.1703G\>T                       p.Ser568Ile                 SNV; missense     Substitution       NA            Heterozygous
                   18:42531008                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(SNV) Single-nucleotide variant, (indel) insertion/deletion.

Copy-number alterations (CNAs) detected by NGS testing were compatible with the karyotyping results of the initial MCL (see above), including loss of Chromosomes 9 and 13, Chromosome arms 6q and 8p, and deletion of 9p21, which includes the CDKN2A/B genes. NGS analysis also revealed gain of the long arm of Chromosome 3, which was most likely represented as the marker chromosome in karyotyping analysis. Comparison of the copy-number profiles of the original MCL and blastoid MCL also showed similar CNAs as described above (deletion of 8p, losses of Chromosomes 9 and 13) and additional genomic imbalances in the blastoid MCL, including gain of Chromosome 6, which override the net copy level of Chromosome 6, gain of Chromosome 7, 11q with *CCND1* involvement (see FISH above) and 15q25--26 ([Fig. 2](#MCS004259TASF2){ref-type="fig"}D,E; [Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)). As CNA analysis is highly dependent on tumor purity, it was not informative in the groin lymph node biopsy involved by CHL because of the rarity of HRS cells (\<20% of total cells; data not shown).

Clonally related HRS-like cells in MCL have only been reported in three prior cases ([Supplemental Table S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1); [@MCS004259TASC11]; [@MCS004259TASC9]; [@MCS004259TASC7]). In these studies, the clonal relationship was established by PCR studies of the *IGHV* regions after microdissection ([@MCS004259TASC11]; [@MCS004259TASC9]) and confirmed by FISH studies showing IGH/*CCND1* translocation in both MCL and HRS-like cells ([@MCS004259TASC11]; [@MCS004259TASC9]; [@MCS004259TASC7]). Our case is exceptional as a bona fide CHL was diagnosed rather than MCL with HRS c-like cells, and a MCL component was not present in the biopsy with CHL either by flow cytometric study (with a sensitivity approaching 0.01%) or immunohistochemical studies ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1); [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)). Our comprehensive analysis provided convincing evidence at multiple levels demonstrating clonal relatedness between MCL and CHL including shared IGH/*CCND1* rearrangements, identical IGHV clonal sequence, and shared mutations of *TP53* p.R248Q*, NSD2* p.E1099K and *IDH1* p.E262K. However, the additional differential genetic aberrations seen between MCL and CHL, such as loss of *CDKN2A/B* and Chromosome 9 in MCL, *PDL1/2* gain, and Chromosome 9 polysomy in CHL, suggest a common precursor clone with a divergent clonal evolution to MCL and CHL. Notably, a subclonal *KMT2D* p.L3542Vfs\*13 (c.10624_10625delCT) mutation was present in the initial MCL, and this mutation became the predominant clone in CHL but was not detected in blastoid MCL, suggesting the clone harboring *KMT2D* p.L3542Vfs\*13 (c.10624_10625delCT) mutation might have evolved to CHL. The blastoid MCL likely originated from a different subclone, which acquired mutations in *SETBP1,* a *KMT2D* variant that was different from the initial variant (p.F3966_Q3971delins\*), and a *SECB22-NOTCH2* fusion. These findings implicate the presence of a common precursor harboring *IGH/CCND1* rearrangements and mutations of *TP53* p.R248Q*, NSD2* p.E1099K, and *IDH1* p.E262K. *KMT2D* p.L3542Vfs\*13 (c.10624_10625delCT) mutation is likely to present in the common precursor, albeit at a subclonal level ([Fig. 2](#MCS004259TASF2){ref-type="fig"}F). The possibility of a linear evolution from the initial MCL to CHL is not favored ([Fig. 2](#MCS004259TASF2){ref-type="fig"}F).

Discussion {#s03}
==========

MCLs are considered to arise from a subset of CD5^+^ naive B cells, whereas a small proportion of MCLs appear to be of post--germinal center (post-GC) origin ([@MCS004259TASC6]). In this case, NGS studies demonstrated an identical rate of IGHV hypermutation in all three lymphomas in our patient indicating a post-GC origin ([@MCS004259TASC11]). The characteristic genetic aberrations of IGH/*CCND1* translocations occur at the pre-B stage ([@MCS004259TASC6]). The hypothetical precursors also had mutations in several genes including *TP53* p.R248Q*, NSD2* p.E1099K, *IDH1* p.E262K, and likely *KMT2D* p.L3542Vfs\*13 (c.10624_10625delCT), a typical MCL mutational profile. These results suggest a common precursor at GC or post-GC stage in our case. Interestingly, the *NOTCH2* inversion event leading to a *SEC22B-NOTCH2* fusion was detected in blastoid MCL. *NOTCH2* mutations and *NOTCH2*'s signaling pathway have been implicated in the pathogenesis of aggressive MCL ([@MCS004259TASC1]). This fusion, initially discovered in triple-negative aggressive breast cancer ([@MCS004259TASC10]), is highly active in up-regulating NOTCH signaling and the expression of downstream targets including CMYC and CCND1 ([@MCS004259TASC10]). The identification of this fusion provides an alternative mechanism of aberrant NOTCH2 signaling in MCL and might also explain the aggressive behavior in this patient.

The underlying mechanisms of a divergent clonal evolution to HRS-like cells and/or CHL in MCL include EBV infection, acquisition of additional genetic aberrations such as *PDL1/2* amplification, and certain mutations in MCL that might contribute to this process such as *TP53*. Interestingly, in our case deregulation of PDL1/2 in the setting of multiple prior genetic aberrations, including *TP53* mutations, might be sufficient to generate the CHL phenotype. The clinical significance of HRS-like cells in MCL remains to be clarified. The reported cases were rarely managed with CHL appropriate regimens ([@MCS004259TASC2]; [@MCS004259TASC13]; [@MCS004259TASC5]; [@MCS004259TASC11]; [@MCS004259TASC4]; [@MCS004259TASC9]; [@MCS004259TASC7]), which is consistent with the current recommendations for management of CLL/SLL with "type I" HRS-like ([@MCS004259TASC12]). Once a diagnosis of bona fide CHL is established, management with CHL appropriate regimen would be reasonable as demonstrated by control of CHL component in this case. It is unclear if CHL changes the clinical course of MCL although our patient had an aggressive clinical course.

METHODS {#s3}
=======

Biopsies were formalin-fixed paraffin-embedded (FFPE) and processed for standard H&E staining and immunohistochemistry. Single-cell suspension was prepared from submitted fresh tissues and subjected to flow cytometric analysis. The bone marrow aspirate specimens were studied with conventional chromosome and FISH analysis. FFPE tissue blocks were also submitted for FISH tests, clonality analysis by IGH gene rearrangement, and targeted next-generation sequencing analysis (see [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004259/-/DC1)).
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